Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The time is now

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Jun 08, 2021 12:06pm

97 Views

Post# 33348033

RE:RE:RE:RE:RE:RE:RE:The time is now

I think one of the things i found most exhausting/frustrating is that the only people right about this stock's performance are the FUDs. News releases have either no impact or minimal impact (and it's short-lived). It's exhausting. I do think that if they cannot start P3 on time, Dan will need to go. I haven't been a big fan of his, but I've also given him the benefit of the doubt. But, you can only say the price of the shares is a bargain for so long...

123ABC wrote: We all need an exit strategy before Dan drives us into an early grave.

IrishCanuck wrote: I think he needs an exit strategy... Phase 3 will drive him to an early grave